This work establishes a practical framework for low-throughput, cost-constrained discovery campaigns capable of delivering chemically tractable binders with favorable property profiles, and introduces a suite of ADMET models for kinetic solubility, lipophilicity, and Caco-2 permeability to improve developability at the point of selection.
Abstract
We present BoltzMol-1, a small-molecule hit discovery pipeline, centered on an optimized version of Boltz-2, explicitly adapted for prospective discovery. Reliable hit discovery that generalizes across target classes (rather than only the well-characterized families that dominate existing ligand data) would broaden the range of biology accessible to small-molecule intervention and reduce reliance on resource-intensive high-throughput screening. Towards this goal, the system prioritizes compounds for rapid experimental validation by coupling model-driven ranking with streamlined procurement from commercial catalogs. To improve developability at the point of selection, we introduce a suite of ADMET models for kinetic solubility (logS), lipophilicity (logD), and Caco-2 permeability. These models act as an early triage layer, systematically filtering out compounds with unfavorable physicochemical and absorption properties prior to synthesis or purchase. Across a panel of ten targets (most with no representation in the underlying affinity training data) we observe strong prospective performance on challenging systems. Functional actives or binders were identified for 6 of 10 targets, despite modest experimental budgets of 28-96 compounds per target. These results include successes on receptors and enzymes traditionally considered difficult for structure- or ligand-based approaches. Collectively, this work establishes a practical framework for low-throughput, cost-constrained discovery campaigns capable of delivering chemically tractable binders with favorable property profiles. Figure 1: Overview of the prospective virtual-screening campaigns across all targets. For each target, the panel shows the predicted protein-ligand complex together with the number of compounds tested, the number of confirmed actives/binders, and the assays used for screening and follow-up.
This work systematically evaluates the performance of a popular ML-based docking method, DiffDock-Pocket, on high-throughput screening (HTS) data sets derived from the PubChem BioAssay database, a premier source of bioactivity data.
Furyal Ahmed, M. Soellner, Charles L. Brooks· Journal of Chemical Informat...· 0 citations
Novo-1, a coarse-grained cofolding framework for binding- affinity prediction, offers more than one order of magnitude speed-up over the leading open-source baseline, Boltz-2, and demonstrates meaningful selectivity, separating the binding affinities of identical compounds between on-targets and related off-targets.
Nikhil Shenoy, David Errington, Emmanuel Bengio et al.· bioRxiv· 3 citations· ⚡1
ComBINAUT is an automated parallel synthesis platform that generates diverse chemical scaffolds to accelerate hit validation and refinement, enabling the efficient exploration of chemical space and the rapid discovery of novel ligands.
Sean M. McKenna, M. Šícho, Cas van der Horst et al.· Journal of the American Chem...· 0 citations
FastBindRank is presented, a distillation-based framework that transfers the predictive power of a high-accuracy structure-based model (Boltz-2) into a computationally efficient sequence-based surrogate and can identify functionally active novel compounds from ultra-large virtual screening.
J. Dai, Yueyue Wang, N. Shan et al.· Clinical Cancer Research· 0 citations
This article proposes an offline/online method that Wisely selects a small number of easy to compute features of both the amino acid sequence of the proteins and the molecular structure of the ligands, and discretises their domains, which induces a low-dimensional finitisation of proteins' and ligands' chemical spaces.
Riccardo Curcio, Toni Mancini, Enrico Tronci· BMC Bioinformatics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.